$50 million says molecular glues could be used for much more

With medical research into molecular glues on the rise, research from Harvard University is finding its way into the local biotech scene.

Massachusetts, USA-based start-up Magnet Biomedicine has announced a $50 million Series A round, with the company targeting a broader use for the compounds, outside of their known applications in protein degradation.

Co-founder Stuart Schreiber brings decades of research experience into the company. Together with chief scientific officer Brian Safina, he argues that molecular glues can be used for more than the established protein to protein interactions.